Status:

TERMINATED

Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19

Lead Sponsor:

Massachusetts General Hospital

Collaborating Sponsors:

University of Alabama at Birmingham

Conditions:

Coronavirus Infections

Pneumonia, Viral

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The scientific community is in search for novel therapies that can help to face the ongoing epidemics of novel Coronavirus (SARS-Cov-2) originated in China in December 2019. At present, there are no p...

Detailed Description

To date, no targeted therapeutic treatments for the ongoing COVID-19 outbreak have been identified. Antiviral combined with adjuvant therapies are currently under investigation. The clinical spectrum ...

Eligibility Criteria

Inclusion

  • Laboratory confirmed COVID19 infection defined with a positive RT-PCR from any specimen and/or detection of SARS-CoV-2 IgM/IgG antibodies.
  • Hospital admission with at least one of the following:
  • fever ≥ 36.6 °C from axillary site; or ≥ 37.2°C from oral site; or ≥ 37.6°C from tympanic or rectal site.
  • Respiratory rate ≥ 24 bpm
  • cough
  • Spontaneous breathing with or without hypoxia of any degree. Gas exchange and ventilation maybe assisted by any continuous continuous airway pressure (CPAP), or any system of Non Invasive Ventilation (NIV), with Positive End-Expiratory Pressure (PEEP) ≤ 10 cmH2O.

Exclusion

  • Tracheostomy
  • Therapy with high flow nasal cannula
  • Any clinical contraindications, as judged by the attending physician
  • Patients enrolled in another interventional study
  • Hospitalized and confirmed diagnosis of COVID-19 for more than 72 hours
  • Previous intubation for COVID-19
  • Patient not committed to full support (DNR, DNI or CMO)
  • Patient requiring oxygen at home for lung comorbidities
  • Primary cause of hopitalization not due to COVID-19

Key Trial Info

Start Date :

March 21 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 23 2023

Estimated Enrollment :

70 Patients enrolled

Trial Details

Trial ID

NCT04305457

Start Date

March 21 2020

End Date

August 23 2023

Last Update

December 17 2025

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Providence HealthCare Network

Anchorage, Alaska, United States, 99508

2

Louisiana State University Health Shreveport

Shreveport, Louisiana, United States, 71103

3

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114-2621